Cardiff Oncology
Logotype for Cardiff Oncology Inc

Cardiff Oncology (CRDF) investor relations material

Cardiff Oncology Study result summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cardiff Oncology Inc
Study result summary27 Jan, 2026

Management transition and strategic focus

  • Leadership transition aims to position the company for late-stage development and maximize onvansertib's value in RAS-mutated metastatic colorectal cancer (mCRC).

  • The transition is driven by promising clinical data, not by issues with the drug program.

  • The interim CEO is supported by experienced operational, scientific, and clinical teams, ensuring continuity.

  • Strategic partnerships and expansion into additional indications are being actively explored.

  • Recruitment for leadership and clinical teams will focus on late-stage development and commercialization expertise.

Phase II study design and patient population

  • The CRDF-004 phase II trial evaluated two doses of onvansertib with FOLFIRI-Bev or FOLFOX-Bev in first-line RAS-mutated mCRC.

  • Patients were randomized to receive 20 mg or 30 mg onvansertib plus standard of care, or standard of care alone.

  • Endpoints included objective response rate, progression-free survival, duration of response, and safety.

  • The patient population represents about 50% of all metastatic CRC cases, highlighting significant unmet need.

  • Baseline characteristics were balanced, with no significant outliers affecting results.

Efficacy and safety results

  • The 30 mg onvansertib plus FOLFIRI-Bev arm showed a confirmed objective response rate (ORR) of 72.2% and median progression-free survival not reached, significantly outperforming standard regimens.

  • Dose-dependent efficacy was observed, with greater benefit at 30 mg; FOLFOX combinations showed less consistent results.

  • The PFS hazard ratio for 30 mg onvansertib plus FOLFIRI-Bev was 0.37 versus standard regimens, achieving statistical significance.

  • Onvansertib with FOLFIRI-Bev was well-tolerated, with no major or unexpected toxicities; neutropenia was the most common grade 3+ adverse event.

  • Results validate previous positive findings from a Phase 2 trial in second-line, bevacizumab-naïve patients.

Registrational trial control arm strategy
PFS statistical significance robustness
Onvansertib's differentiation vs current SoC
Rationale for dual SOC control in registrational study
Partnership strategy for Phase III funding/expansion
FOLFOX arm efficacy trends vs FOLFIRI arm
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Cardiff Oncology earnings date

Logotype for Cardiff Oncology Inc
Q4 202527 Feb, 2026
Cardiff Oncology
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Cardiff Oncology earnings date

Logotype for Cardiff Oncology Inc
Q4 202527 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Cardiff Oncology Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for various cancers. The company's primary approach involves leveraging PLK1 (Polo-like Kinase 1) inhibition to create novel cancer treatments. Their flagship product, onvansertib, is an oral selective PLK1 inhibitor currently being evaluated in combination with standard-of-care therapeutics across several clinical programs. These include treatments for KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage